TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07208058: An Open-label, Single-arm, Multicenter, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemop

Sponsor: TJ Biopharma Co., Ltd. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT07208058 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07208058 Rescue Dossier →